Schnitzler’s syndrome - a novel hypothesis of a shared pathophysiologic mechanism with Waldenström’s disease

[1]  J. Fischer,et al.  Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo‐controlled study , 2017, The Journal of allergy and clinical immunology.

[2]  P. Jansen,et al.  Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. , 2015, The Journal of allergy and clinical immunology.

[3]  H. Koning.  Schnitzler's syndrome: lessons from 281 cases. , 2014 .

[4]  L. Schnitzler,et al.  Schnitzler's syndrome: diagnosis, treatment, and follow‐up , 2013, Allergy.

[5]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[6]  P. Chilton,et al.  Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation , 2012, Front. Immun..

[7]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[8]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[9]  J. Mueller,et al.  Initial description of the human NLRP3 promoter , 2008, Genes and Immunity.

[10]  B. Guillot,et al.  Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome. , 2008, Acta dermato-venereologica.

[11]  J. V. D. van der Meer,et al.  Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. , 2007, Seminars in arthritis and rheumatism.

[12]  C. Morton,et al.  Characterization of familial Waldenstrom's Macroglobulinemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Blanco,et al.  Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. , 2005, Arthritis and rheumatism.

[14]  T. Therneau,et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.

[15]  P. Feng,et al.  IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.

[16]  J. Clauvel,et al.  Chronic urticaria with monoclonal IgM--a report of five cases. , 1982, Clinical Immunology and Immunopathology.

[17]  N. Kluger,et al.  Dysphonia revealing early syphilis. , 2008, Acta dermato-venereologica.

[18]  M. C. R. Machado,et al.  Schnitzler's syndrome without monoclonal gammopathy. , 2005, Acta dermato-venereologica.

[19]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..